In a David-and-Goliath lawsuit kept under wraps for two years in arbitration, a tiny drug research company in Spain won its case against a U.S. pharmaceutical giant in February, clearing the way to begin manufacturing its new drug.
The arbitration stretched over five days as international experts debated the scientific procedures used to produce the drug. In the end, the methods used by the R&D company were fully vindicated. Within days, the big pharma company paid damages, thereby under the arbitration rules avoiding disclosure of its identity.
